The emerging treatment of RNA interference (RNAi) has drawn considerable attention from cancer researchers over the past decade because of their distinct ability to silence onco-related genes.However,its clinical application is greatly limited due to specific challenges related to the delivery of siRNA to the cytoplasm,which is the site of action for RNAi,especially the efficient escape of siRNA from the endosomes.Among a variety of siRNA delivery systems,lipid-based siRNA carriers exhibit desirable clinical application potential because of their favorable safety and biocompatibility[1-3].